𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

✍ Scribed by Patrick J. Creaven; Dean E. Brenner; J. Wayne Cowens; Robert P. Huben; Richard M. Wolf; Hiroshi Takita; Susan G. Arbuck; Mohamed S. Razack; April D. Proefrock

Publisher
Springer
Year
1989
Tongue
English
Weight
510 KB
Volume
23
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I clinical trial of ixabepilone
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
✍ Sen H. Zhuang; Manish Agrawal; Maureen Edgerly; Susan Bakke; Herb Kotz; Paul Tha 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND The epothilones are a novel class of microtubule‐stabilizing agents. Ixabepilone (BMS‐247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B. The authors conducted a Phase I study by administering ixabepilone to patients as a 1‐hour intravenous

Recombinant human anti–transforming grow
Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place